
Relacorilant Plus Chemo Meets Primary Goal in Ovarian Cancer Trial
The primary end goal was met in a phase 3 trial of relacorilant plus nab-paclitaxel chemotherapy in patients with platinum resistant ovarian cancer, which improved progression-free survival, according to the drug’s manufacturer, Corcept Therapeutics Inc. …